Alaunos Therapeutics (NASDAQ:TCRT) Shares Up 13.8%

Alaunos Therapeutics, Inc. (NASDAQ:TCRT)’s stock price rose 13.8% during trading on Friday . The company traded as high as $1.34 and last traded at $1.32. Approximately 50,846 shares were traded during trading, a decline of 73% from the average daily volume of 185,626 shares. The stock had previously closed at $1.16.

Alaunos Therapeutics Stock Up 13.8 %

The company’s 50 day simple moving average is $1.71 and its two-hundred day simple moving average is $1.57. The company has a market capitalization of $21.13 million, a price-to-earnings ratio of -0.55 and a beta of -0.33.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Alaunos Therapeutics stock. Magnolia Capital Advisors LLC purchased a new stake in shares of Alaunos Therapeutics, Inc. (NASDAQ:TCRT) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 432,969 shares of the company’s stock, valued at approximately $56,000. Magnolia Capital Advisors LLC owned approximately 0.18% of Alaunos Therapeutics at the end of the most recent quarter. Institutional investors own 27.72% of the company’s stock.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor engine.